HMGB1在卵巢癌中的表达及临床意义  

Expression and clinical significance of HMGB1 in ovarian carcinoma

作　　者：贺小燕[1] 王海琳[2] 陈晓红[1] 陈丑彦[1] 

机构地区：[1]兰州大学第一临床医学院,甘肃兰州730000 [2]甘肃省人民医院妇产科,甘肃兰州730000

出　　处：《现代生物医学进展》2011年第4期695-697,共3页Progress in Modern Biomedicine

摘　　要：目的:探讨高迁移率组蛋白B1(HMGB1)在卵巢癌患者血清及组织中的表达及临床意义。方法:采用ELISA技术检测96例女性血清中HMGB1水平,其中盆腔肿物住院患者66例按照术后病理结果分为卵巢良性肿瘤组40例和卵巢癌组26例,健康女性30例作为正常对照组,并通过免疫组织化学技术进一步检测卵巢癌、卵巢良性肿瘤组织中的表达情况。结果:卵巢癌组HMGB1水平明显高于其他两组,差异有统计学意义(P<0.05),正常对照组和卵巢良性肿瘤组比较差异无统计学意义(P>0.05)。结论:HMGB1测定有助于鉴别卵巢良恶性肿瘤。Objective：To explore the expression and clinical significance of HMGB1 in ovarian carcinoma.Methods：ELISA method was used to detect the expression of serum HMGB1 in 26 ovarian carcinoma,40 benign ovarian tumor and 30 healthy women.Moreover,Immunohistochemical SABC method was used to detect the expression of HMGB1 in 26 ovarian carcinoma tissues and 40 benign ovarian tumor tissues.Results：The expression of HMGB1 were higher in ovarian carcinoma than that in the others,showing a significant difference（P0.05）.There were no significant diference between normal control group and benign ovarian tumor group（P0.05）.Conclusion：The expression of HMGB1 might be as one of the parameters for identifying benign ovarian tumor and ovarian carcinoma.

关 键 词：HMGB1 卵巢癌 肿瘤标志物 免疫组织化学 

分 类 号：R737.31[医药卫生—肿瘤]